19 recruiting. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Recruiting 19 |
| Phase 2 | 8 | Recruiting 8 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabidiol Oil for Treatment-Resistant Major Depression Full-spectrum CBD oil 100 mg/mL, Placebo oil (MCT oil) - Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 120 | 2026-06-01 | 2026-07-10 |
| Pattern Separation in Major Depressive Disorder SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Jeffrey Miller | 30 | 2026-06-01 | 2026-09-15 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder ExAblate Neuro 4000 - Anorexia Nervosa (DSM-IV Revised Criteria) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-08-01 | 2025-08-14 |
| Theta-Burst Stimulation to Treat Depression Spaced iTBS, Compressed iTBS - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Centre for Addiction and Mental Health | 84 | 2025-06-01 | 2025-06-24 |
| Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery Ketamine (Ketalar) - Pain, Postpartum Depression | Phase 1 | Recruiting | University of Utah | 50 | 2025-03-28 | 2026-10-02 |
| Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains transcutaneous spinal direct current stimulation - Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | University of Cincinnati | 67 | 2025-02-25 | 2026-08-03 |
| qEEG Brain Signature of Depression & Neuromodulation-induced Recovery Transcranial Magnetic Stimulation - Major Depressive Diorder | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 100 | 2025-01-06 | 2025-03-03 |
| Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels Low-intensity TMS, Transcranial Magnetic Stimulation Sham - Depression - Major Depressive Disorder, Transcranial Magnetic Stimulation | Phase 1 / Phase 2 | Recruiting | Universidad de Guanajuato | 40 | 2024-10-28 | 2025-05-08 |
| Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression Psilocybin and Psilocyn, Placebo, Psychotherapy-assisted session - Depressive Disorder | Phase 1 / Phase 2 | Recruiting | Federal University of Latin American Integration | 24 | 2024-09-05 | 2026-03-27 |
| Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression Ketamine, Saline - Healthy, Major Depressive Disorder | Phase 1 | Recruiting | Texas A&M University | 100 | 2024-01-01 | 2026-09-15 |
| DBS for Depression Medtronic SenSight Directional DBS lead - Treatment Resistant Depression | Phase 1 | Recruiting | Northwell Health | 20 | 2023-10-18 | 2026-09-14 |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Ketamine, Perampanel, Placebo - Depressive Disorder, Major, Post Traumatic Stress Disorder | Phase 1 | Recruiting | Yale University | 50 | 2023-09-07 | 2026-05-06 |
| Enoxolone in Major Depression - Biomarker-outcome Relationship Enoxolone - Unipolar Depression | Phase 1 / Phase 2 | Recruiting | Philipps University Marburg | 80 | 2022-09-23 | 2025-12-08 |
| Neural Response to Inflammatory Challenge in Major Depressive Disorder LPS, Saline - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | Laureate Institute for Brain Research, Inc. | 180 | 2021-05-15 | 2026-04-21 |
| Maternal Mental Health Trial Transdermal patch estradiol, Transdermal patch placebo - Major Depressive Disorder, Postpartum Depression | Phase 1 / Phase 2 | Recruiting | Vibe G Frøkjær, MD, PhD | 220 | 2021-02-03 | 2021-09-23 |
| Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions - Depression, Major Depressive Disorder | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 70 | 2020-01-21 | 2026-09-10 |
| Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder Ketamine, Placebo, Cobot TS MV robotic arm for TMS - Healthy Volunteer, Major Depressive Disorder | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 150 | 2017-05-25 | 2026-10-26 |
| NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits Nitrous Oxide, Placebo gas, MRI - Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | Phase 1 | Recruiting | Washington University School of Medicine | 60 | 2017-01-27 | 2026-04-29 |
Depressive Disorder, Major (15) · Depression (8) · Depressive Disorder, Treatment-Resistant (5) · Depression, Postpartum (2) · Mood Disorders (2) · Anorexia Nervosa (1) · Mental Disorders (1) · Obsessive-Compulsive Disorder (1) · Pain (1) · Schizophrenia (1) · Stress Disorders, Post-Traumatic (1)
Mental Disorders (18) · Mood Disorders (17) · Behavior (8) · Behavioral Symptoms (8) · Female Urogenital Diseases and Pregnancy Complications (2) · Pregnancy Complications (2) · Puerperal Disorders (2) · Urogenital Diseases (2) · Anxiety Disorders (1) · Feeding and Eating Disorders (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Signs and Symptoms (1)
Ketamine (4) · Sodium Chloride (2) · Transcranial Magnetic Stimulation (2) · Escitalopram (1) · Fluoxetine (1) · Glycyrrhetinic Acid (1) · Nitrous Oxide (1) · Psilocybin (1) · Selective Serotonin Reuptake Inhibitors (1) · Sertraline (1) · cariprazine (1) · perampanel (1)
National Institute of Mental Health (NIMH) (2) · Sunnybrook Health Sciences Centre (2) · Centre for Addiction and Mental Health (1) · Federal University of Latin American Integration (1) · Jeffrey Miller (1) · Laureate Institute for Brain Research, Inc. (1) · Mapi Pharma Ltd. (1) · Northwell Health (1) · Philipps University Marburg (1) · Texas A&M University (1) · Universidad de Guanajuato (1) · Universidade do Sul de Santa Catarina (1) · University of Cincinnati (1) · University of Utah (1) · Vibe G Frøkjær, MD, PhD (1)
United States (10) · Canada (3) · Brazil (2) · Denmark (1) · Germany (1) · India (1) · Israel (1) · Mexico (1)
Carlos A Zarate, M.D. (2) · Albert J Fenoy, MD (1) · Charles R Conway, MD (1) · Francisco Romo-Nava, MD, PhD (1) · Francisney P Nascimento, 1 (1) · Grace Lim, MD, MSc (1) · Harald Murck, MD PhD (1) · Jeffrey M Miller, MD (1) · John Krystal, MD (1) · Ma. Eugenia Garay Sevilla, PhD in medical sciences (1) · Naomi R Driesen, Ph.D. (1) · Olga E Escobar Florez, Master of Medical Sciences (1)
PMID 35501309, PMID 35763351, PMID 37585253, PMID 39185528
R01MH129371 (1), R01MH134538 (1), R61MH133770 (1)